All In Biotech

Free tool

FAERS Monitor: Cobenfy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216158 or its brand name (Cobenfy, Trospium Chloride, Xanomeline Tartrate). Reports on generic versions are filed under their own applications.

Reports

2,767

Serious

669

24% of reports

Hospitalization

249

Death reported

29

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea593
  • vomiting439
  • constipation202
  • off label use195
  • urinary retention153
  • dizziness127
  • dyspepsia112
  • hyperhidrosis97
  • vision blurred92
  • drug ineffective84
  • dry mouth82
  • heart rate increased65
  • treatment noncompliance65
  • somnolence63
  • gastrointestinal disorder62

Reports by year received

View as table
YearReports
2024172
20251,254
20261,341

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,392 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
urinary retentionSignal15335.030.05,007
treatment noncomplianceSignal659.07.1457
dyspepsiaSignal1128.77.2754
dry mouthSignal827.76.2472
vomitingSignal4397.16.52,346
constipationSignal2027.06.21,052
hyperhidrosisSignal975.74.7376
nauseaSignal5935.75.32,381
gastrointestinal disorderSignal625.34.1211
vision blurredSignal925.14.2301
heart rate increasedSignal655.03.9204
somnolenceSignal632.41.949
dizziness1271.91.658
off label use1951.71.557
drug ineffective840.50.449

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.